CEACAM7 and inflammatory bowel disease: Neither CEACAM7 nor CEACAM3 has previously been studied in IBD, although a reduction in CEACAM7 and CEACAM3 was reported in patients in stage II recurrent and non-recurrent colorectal cancer (25) and in the post-operative phase of patients with colorectal cancer, respectively (26).